Do patients with intermediate-risk renal carcinoma who receive adjuvant pembrolizumab really benefit in recurrence-free survival? Analysis of a cohort of nephrectomies over 10 years - Rojas, Pablo A; Carracedo, David; Moscatiello, Pietro; Gonzalez, Laura; Gimbernat, Helena; Santiago, Marta; Toledo, Miguel; Pereira, Nathalie; Sanchez-Encinas, Miguel (World Journal Of Urology, 2025)